MedPath

Efficacy and Safety of IQP-VV-102 in Weight Management

Phase 3
Completed
Conditions
Overweight
Obesity
Interventions
Dietary Supplement: IQP-VV-102
Other: Placebo
Registration Number
NCT01681069
Lead Sponsor
InQpharm Group
Brief Summary

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Age 18 to 60 years
  • 25 kg/m2 ≤ BMI ≤ 35 kg/m2
  • Written informed consent
Exclusion Criteria
  • Known sensitivity to sources of the active ingredients and excipients
  • Pregnancy or nursing
  • Inability to comply with study requirements, e.g. due to language difficulties
  • Participation in another study during the last 30 days of the screening visit

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IQP-VV-102IQP-VV-1022 tablets twice a day
PlaceboPlacebo2 tablets twice a day
Primary Outcome Measures
NameTimeMethod
Change in Body Weight at End of Study Compared to Baseline12 weeks

Change in body weight at the end of study compared to baseline

Secondary Outcome Measures
NameTimeMethod
Change in Waist Circumference (in cm) at End of Study From Baseline12 weeks

Difference in waist circumference (in cm) at end of study from baseline

Change in Mean Body Fat at End of Study From Baseline12 weeks

Measured in kg using calibrated weighing scales

Trial Locations

Locations (1)

Barbara Grube

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath